You can buy or sell MACK and other stocks, options, ETFs, and crypto commission-free!
Merrimack Pharmaceuticals, Inc. Common Stock, also called Merrimack Pharmaceuticals, is a clinical stage biopharmaceutical company, which engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Read More Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Yahoo FinanceMar 7
Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4
Merrimack Pharmaceuticals, Inc. MACK incurred a loss of 97 cents per share for the fourth quarter of 2018, narrower than the Zacks Consensus Estimate of a loss of $1.01 per share but wider than the year-ago quarter’s loss of 89 cents. Merrimack sold its only marketed product, Onivyde, to Ipsen in 2017. As a result, the company could not generate any revenues in the reported quarter in want of a marketed product in its portfolio. Shares of Merrimack were almost 6.5% up following its release of fourth-quart...
PR NewswireMar 6
Merrimack Reports Fourth Quarter and Full Year 2018 Financial Results
CAMBRIDGE, Mass., March 6, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced its fourth quarter and full year 2018 financial results for the period ended December 31, 2018. "Last quarter, we engaged external advisors and initiated a process to explore Merrimack's strategic alternatives. This is an active process that we are working expeditiously to bring to conclusion, with a range of potential outcom...
Expected May 7, Pre-Market